Increased serum cathepsin S in patients with atherosclerosis and diabetes

Jian Liu, Likun Ma, Jintian Yang, An Ren, Zimin Sun, Gengxing Yan, Jiusong Sun, Huanxian Fu, Weihua Xu, Chengcheng Hu, Guo Ping Shi

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Atherosclerosis and diabetes are closely associated and both involve extensive degradation of the aortic elastin. Increased elastase activity has been detected in diabetic animal aortae. We have demonstrated enhanced elastolytic cathepsin S in human atherosclerotic lesions but insufficient amounts of its endogenous inhibitor cystatin C, suggesting alterations of serum cathepsin S and/or cystatin C in patients with atheroslcerosis or diabetes. In this study, we measured levels of both cathepsin S and cystatin C in sera from 240 patients by ELISA. Among these patients, 107 had a diagnosis of atherosclerotic stenosis, 103 were diabetic, and 30 had neither condition. Multiple linear regression analysis demonstrated that significantly higher serum levels of cathepsin S in patients with either atherosclerotic stenosis (p < 0.04) or diabetes (p = 0.0005) persisted after adjustment for cystatin C level, renal function, smoking, and serum glucose levels (p = 0.008, p = 0.0005). Furthermore, patients with acute (p = 0.009) or previous myocardial infarction (p < 0.02) or unstable angina pectoris (p < 0.05) had elevated levels of cathepsin S after adjustment for smoking, creatinine, cystatin C, and serum glucose. In contrast, serum cystatin C levels were higher in diabetic patients (p = 0.00001), but not in atherosclerotic subjects (p = 0.14), than in the non-involved population after adjustment for age, smoking, and renal function. Although the pathophysiology of cathepsin S or cystatin C in atherosclerosis and diabetes requires further investigation, increased serum cathepsin S may serve as a biomarker for both diseases.

Original languageEnglish (US)
Pages (from-to)411-419
Number of pages9
JournalAtherosclerosis
Volume186
Issue number2
DOIs
StatePublished - Jun 2006
Externally publishedYes

Fingerprint

cathepsin S
Cystatin C
Atherosclerosis
Cathepsin C
Serum
Smoking
Pathologic Constriction
Kidney
Glucose
Elastin
Pancreatic Elastase
Unstable Angina
Aorta
Linear Models
Creatinine

Keywords

  • Atherosclerosis
  • Cathepsin S
  • Cystatin C
  • Diabetes
  • Myocardial infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Liu, J., Ma, L., Yang, J., Ren, A., Sun, Z., Yan, G., ... Shi, G. P. (2006). Increased serum cathepsin S in patients with atherosclerosis and diabetes. Atherosclerosis, 186(2), 411-419. https://doi.org/10.1016/j.atherosclerosis.2005.08.001

Increased serum cathepsin S in patients with atherosclerosis and diabetes. / Liu, Jian; Ma, Likun; Yang, Jintian; Ren, An; Sun, Zimin; Yan, Gengxing; Sun, Jiusong; Fu, Huanxian; Xu, Weihua; Hu, Chengcheng; Shi, Guo Ping.

In: Atherosclerosis, Vol. 186, No. 2, 06.2006, p. 411-419.

Research output: Contribution to journalArticle

Liu, J, Ma, L, Yang, J, Ren, A, Sun, Z, Yan, G, Sun, J, Fu, H, Xu, W, Hu, C & Shi, GP 2006, 'Increased serum cathepsin S in patients with atherosclerosis and diabetes', Atherosclerosis, vol. 186, no. 2, pp. 411-419. https://doi.org/10.1016/j.atherosclerosis.2005.08.001
Liu, Jian ; Ma, Likun ; Yang, Jintian ; Ren, An ; Sun, Zimin ; Yan, Gengxing ; Sun, Jiusong ; Fu, Huanxian ; Xu, Weihua ; Hu, Chengcheng ; Shi, Guo Ping. / Increased serum cathepsin S in patients with atherosclerosis and diabetes. In: Atherosclerosis. 2006 ; Vol. 186, No. 2. pp. 411-419.
@article{37edbf3ef1da4fb591cc9e277480d9e4,
title = "Increased serum cathepsin S in patients with atherosclerosis and diabetes",
abstract = "Atherosclerosis and diabetes are closely associated and both involve extensive degradation of the aortic elastin. Increased elastase activity has been detected in diabetic animal aortae. We have demonstrated enhanced elastolytic cathepsin S in human atherosclerotic lesions but insufficient amounts of its endogenous inhibitor cystatin C, suggesting alterations of serum cathepsin S and/or cystatin C in patients with atheroslcerosis or diabetes. In this study, we measured levels of both cathepsin S and cystatin C in sera from 240 patients by ELISA. Among these patients, 107 had a diagnosis of atherosclerotic stenosis, 103 were diabetic, and 30 had neither condition. Multiple linear regression analysis demonstrated that significantly higher serum levels of cathepsin S in patients with either atherosclerotic stenosis (p < 0.04) or diabetes (p = 0.0005) persisted after adjustment for cystatin C level, renal function, smoking, and serum glucose levels (p = 0.008, p = 0.0005). Furthermore, patients with acute (p = 0.009) or previous myocardial infarction (p < 0.02) or unstable angina pectoris (p < 0.05) had elevated levels of cathepsin S after adjustment for smoking, creatinine, cystatin C, and serum glucose. In contrast, serum cystatin C levels were higher in diabetic patients (p = 0.00001), but not in atherosclerotic subjects (p = 0.14), than in the non-involved population after adjustment for age, smoking, and renal function. Although the pathophysiology of cathepsin S or cystatin C in atherosclerosis and diabetes requires further investigation, increased serum cathepsin S may serve as a biomarker for both diseases.",
keywords = "Atherosclerosis, Cathepsin S, Cystatin C, Diabetes, Myocardial infarction",
author = "Jian Liu and Likun Ma and Jintian Yang and An Ren and Zimin Sun and Gengxing Yan and Jiusong Sun and Huanxian Fu and Weihua Xu and Chengcheng Hu and Shi, {Guo Ping}",
year = "2006",
month = "6",
doi = "10.1016/j.atherosclerosis.2005.08.001",
language = "English (US)",
volume = "186",
pages = "411--419",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Increased serum cathepsin S in patients with atherosclerosis and diabetes

AU - Liu, Jian

AU - Ma, Likun

AU - Yang, Jintian

AU - Ren, An

AU - Sun, Zimin

AU - Yan, Gengxing

AU - Sun, Jiusong

AU - Fu, Huanxian

AU - Xu, Weihua

AU - Hu, Chengcheng

AU - Shi, Guo Ping

PY - 2006/6

Y1 - 2006/6

N2 - Atherosclerosis and diabetes are closely associated and both involve extensive degradation of the aortic elastin. Increased elastase activity has been detected in diabetic animal aortae. We have demonstrated enhanced elastolytic cathepsin S in human atherosclerotic lesions but insufficient amounts of its endogenous inhibitor cystatin C, suggesting alterations of serum cathepsin S and/or cystatin C in patients with atheroslcerosis or diabetes. In this study, we measured levels of both cathepsin S and cystatin C in sera from 240 patients by ELISA. Among these patients, 107 had a diagnosis of atherosclerotic stenosis, 103 were diabetic, and 30 had neither condition. Multiple linear regression analysis demonstrated that significantly higher serum levels of cathepsin S in patients with either atherosclerotic stenosis (p < 0.04) or diabetes (p = 0.0005) persisted after adjustment for cystatin C level, renal function, smoking, and serum glucose levels (p = 0.008, p = 0.0005). Furthermore, patients with acute (p = 0.009) or previous myocardial infarction (p < 0.02) or unstable angina pectoris (p < 0.05) had elevated levels of cathepsin S after adjustment for smoking, creatinine, cystatin C, and serum glucose. In contrast, serum cystatin C levels were higher in diabetic patients (p = 0.00001), but not in atherosclerotic subjects (p = 0.14), than in the non-involved population after adjustment for age, smoking, and renal function. Although the pathophysiology of cathepsin S or cystatin C in atherosclerosis and diabetes requires further investigation, increased serum cathepsin S may serve as a biomarker for both diseases.

AB - Atherosclerosis and diabetes are closely associated and both involve extensive degradation of the aortic elastin. Increased elastase activity has been detected in diabetic animal aortae. We have demonstrated enhanced elastolytic cathepsin S in human atherosclerotic lesions but insufficient amounts of its endogenous inhibitor cystatin C, suggesting alterations of serum cathepsin S and/or cystatin C in patients with atheroslcerosis or diabetes. In this study, we measured levels of both cathepsin S and cystatin C in sera from 240 patients by ELISA. Among these patients, 107 had a diagnosis of atherosclerotic stenosis, 103 were diabetic, and 30 had neither condition. Multiple linear regression analysis demonstrated that significantly higher serum levels of cathepsin S in patients with either atherosclerotic stenosis (p < 0.04) or diabetes (p = 0.0005) persisted after adjustment for cystatin C level, renal function, smoking, and serum glucose levels (p = 0.008, p = 0.0005). Furthermore, patients with acute (p = 0.009) or previous myocardial infarction (p < 0.02) or unstable angina pectoris (p < 0.05) had elevated levels of cathepsin S after adjustment for smoking, creatinine, cystatin C, and serum glucose. In contrast, serum cystatin C levels were higher in diabetic patients (p = 0.00001), but not in atherosclerotic subjects (p = 0.14), than in the non-involved population after adjustment for age, smoking, and renal function. Although the pathophysiology of cathepsin S or cystatin C in atherosclerosis and diabetes requires further investigation, increased serum cathepsin S may serve as a biomarker for both diseases.

KW - Atherosclerosis

KW - Cathepsin S

KW - Cystatin C

KW - Diabetes

KW - Myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=33646518541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646518541&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2005.08.001

DO - 10.1016/j.atherosclerosis.2005.08.001

M3 - Article

C2 - 16140306

AN - SCOPUS:33646518541

VL - 186

SP - 411

EP - 419

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 2

ER -